Response to chemotherapy estimates by FDG PET is an important prognostic factor in patients with Ewing sarcoma

Autor: Maria Wieczorek, Katarzyna Bilska, Monika Pogorzała, Grazyna Sobol, M. Dziuk, Katarzyna Połczyńska, Katarzyna Muszyńska-Rosłan, Carlos Rodriguez-Galindo, Elżbieta Michalak, Magdalena Rychlowska-Pruszynska, Radosław Chaber, Katarzyna Drabko, Anna Raciborska
Rok vydání: 2015
Předmět:
Male
Cancer Research
medicine.medical_specialty
Pathology
Prognostic factor
Multivariate analysis
Adolescent
medicine.medical_treatment
Bone Neoplasms
Kaplan-Meier Estimate
Sarcoma
Ewing
Multimodal Imaging
030218 nuclear medicine & medical imaging
03 medical and health sciences
Young Adult
0302 clinical medicine
Fluorodeoxyglucose F18
Antineoplastic Combined Chemotherapy Protocols
Medicine
Humans
In patient
Child
Proportional Hazards Models
Retrospective Studies
Chemotherapy
business.industry
Disease progression
General Medicine
medicine.disease
Prognosis
Predictive value
Treatment Outcome
Oncology
030220 oncology & carcinogenesis
Child
Preschool
Positron-Emission Tomography
Disease Progression
Histopathology
Female
Sarcoma
Radiopharmaceuticals
business
Nuclear medicine
Tomography
X-Ray Computed
Zdroj: Clinicaltranslational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico. 18(2)
ISSN: 1699-3055
Popis: Response to chemotherapy is a prognostic factor in patients with Ewing sarcoma (ES); the role of FDG PET to predict response in these patients has not been thoroughly investigated. We evaluated the diagnostic accuracy and the potential of FDG PET to predict response to chemotherapy (CHT). We analyzed data of 50 patients with ES (median age 12.6 years). All patients were treated with neoadjuvant CHT, and underwent surgery for local control. All patients had 18F-FDG PET/CT at diagnosis and after induction CHT, prior to local control. We compared response assessed by histopathology with FDG PET using standard uptake values (SUVs). Median SUV at diagnosis (SUV I) was 5 (range 1.2–17), and median SUV after neoadjuvant chemotherapy (SUV II) was 1.8 (range 0–8.4). Median SUV II/I ratio was 0.3 (range 0–1). SUV at diagnosis was significantly lower in patients with good histological response than in patients with poor histological response (median 3.8 vs. 7.2, p 0.02). We found a significant correlation between SUV II and outcome; the positive predictive value of an SUV II ≤ 2.5 for favorable response was 84.21 %, and the median SUV II was significantly higher in patients with disease progression (2.3 vs. 1.6, p = 0.04). In multivariate analysis, necrosis and SUV II were significant predictors of outcome. 18F-FDG PET demonstrates high diagnostic accuracy for response to initial chemotherapy in patients with ES and it correlates with outcome. The role of FDG PET in predicting response and outcome should be further investigated.
Databáze: OpenAIRE
Externí odkaz: